Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit

Genes and Development

Volumn 24, Issue 20, 2010, Pages 2276-2281

  Khaled, Mehdi ^a   Levy, Carmit ^a   Fisher, David E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

cAMP; MITF; PDE4D; Pigmentation; Skin

Indexed keywords

CYCLIC AMP; INTERMEDIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PHOSPHODIESTERASE 4D3; PHOSPHODIESTERASE IV; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; ENZYME ANALYSIS; GEL ELECTROPHORESIS; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MELANOCYTE; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PIGMENT CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN PIGMENTATION; TRANSCRIPTION REGULATION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; FEEDBACK, PHYSIOLOGICAL; FORSKOLIN; HOMEOSTASIS; HUMANS; IMMUNOBLOTTING; INFANT, NEWBORN; MALE; MELANINS; MELANOCYTE-STIMULATING HORMONES; MELANOCYTES; MICE; MICE, INBRED C57BL; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; PHOSPHODIESTERASE INHIBITORS; PROTEIN BINDING; RNA INTERFERENCE; ROLIPRAM; SIGNAL TRANSDUCTION; SKIN;

EID: 77958617776     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1937710     Document Type: Article

References (31)

1. Bentley NJ, Eisen T, Goding CR. 1994. Melanocyte-specific expression of the human tyrosinase promoter: Activation by the microphthalmia gene product and role of the initiator. Mol Cell Biol 14: 7996-8006.
2. Bertolotto C, Abbe P, Hemesath TJ, Bille K, Fisher DE, Ortonne JP, Ballotti R. 1998. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J Cell Biol 142: 827-835.
3. Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernandez M, Schratzer M, Troisfontaines B, von Frenckell R, Wachtel H. 1988. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci 238: 2-6.
4. Busca R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychene A, Ortonne JP, Ballotti R. 2000. Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J 19: 2900-2910.
5. Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, Denat L, Larue L, Goding CR. 2005. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433: 764-769.
6. Conti M, Beavo J. 2007. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481-511.
7. D'Orazio JA, Nobuhisa T, Cui R, Arya M, Spry M, Wakamatsu K, Igras V, Kunisada T, Granter SR, Nishimura EK, et al. 2006. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature 443: 340-344.
8. D'Sa C, Tolbert LM, Conti M, Duman RS. 2002. Regulation of cAMP-specific phosphodiesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons. J Neurochem81: 745-757.
9. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR, Fisher DE. 2004. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6: 565-576.
10. Fitzpatrick TB. 1988. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 124: 869-871.
11. Fitzpatrick TB, Sober AJ. 1985. Sunlight and skin cancer. N Engl J Med 313: 818-820.
12. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, et al. 2005. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117-122.
13. Griswold DE, Webb EF, Breton J, White JR, Marshall PJ, Torphy TJ. 1993. Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. Inflammation 17: 333-344.
14. Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, Valgeirsdottir S, Bergsteinsdottir K, Schepsky A, Dummer R, et al. 2008. Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res 21: 665-676.
15. Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, Houslay MD. 1999. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J 18: 893-903.
16. Houslay MD, Baillie GS, Maurice DH. 2007. cAMP-specific phosphodiesterase-4 enzymes in the cardiovascular system: A molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 100: 950-966.
17. Kunisada T, Lu SZ, Yoshida H, Nishikawa S, Mizoguchi M, Hayashi S, Tyrrell L, Williams DA, Wang X, Longley BJ. 1998. Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J Exp Med 187: 1565-1573.
18. Le Pape E, Wakamatsu K, Ito S, Wolber R, Hearing VJ. 2008. Regulation of eumelanin/pheomelanin synthesis and visible pigmentation in melanocytes by ligands of the melanocortin 1 receptor. Pigment Cell Melanoma Res 21: 477-486.
19. Lerner AB, McGuire JS. 1961. Effect of a- and b-melanocyte stimulating hormones on the skin colour of man. Nature 189: 176-179.
20. Levy C, Khaled M, Fisher DE. 2006. MITF: Master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 12: 406-414. (Pubitemid 44291572)
21. Lin JY, Fisher DE. 2007. Melanocyte biology and skin pigmentation. Nature 445: 843-850.
22. Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E, van Heeke G, Houslay MD. 2005. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with barrestin to control the protein kinase A/AKAP79-mediated switching of the β2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem 280: 33178-33189. (Pubitemid 41397113)
23. MacKenzie SJ, Baillie GS, McPhee I, MacKenzie C, Seamons R, McSorley T, Millen J, Beard MB, van Heeke G, Houslay MD. 2002. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). Br J Pharmacol 136: 421-433. (Pubitemid 34620523)
24. Omori K, Kotera J. 2007. Overview of PDEs and their regulation. Circ Res 100: 309-327.
25. Park SB, Suh DH, Youn JI. 1999. A long-term time course of colorimetric evaluation of ultraviolet light-induced skin reactions. Clin Exp Dermatol 24: 315-320.
26. Price ER, Horstmann MA, Wells AG, Weilbaecher KN, Takemoto CM, Landis MW, Fisher DE. 1998. α-Melanocyte-stimulating hormone signaling regulates expression of microphthalmia, a gene deficient in Waardenburg syndrome. J Biol Chem 273: 33042-33047.
27. Richter W, Jin SL, Conti M. 2005. Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Biochem J 388: 803-811.
28. Rijken F, Bruijnzeel PL, van Weelden H, Kiekens RC. 2004. Responses of black and white skin to solar-simulating radiation: Differences in DNA photodamage, infiltrating neutrophils, proteolytic enzymes induced, keratinocyte activation, and IL-10 expression. J Invest Dermatol 122: 1448-1455.
29. Sette C, Conti M. 1996. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem 271: 16526-16534.
30. Sturm RA, Duffy DL, Box NF, Chen W, Smit DJ, Brown DL, Stow JL, Leonard JH, Martin NG. 2003. The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes. Pigment Cell Res 16: 266-272.
31. Yasumoto K, Yokoyama K, Shibata K, Tomita Y, Shibahara S. 1994. Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol Cell Biol 14: 8058-8070.